Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13174MR)

This product GTTS-WQ13174MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF4 gene. The antibody can be applied in Acute myeloid leukemia (AML), Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_003327.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7293
UniProt ID P43489
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13174MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8217MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA hLIV22
GTTS-WQ3670MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY 1213790
GTTS-WQ9398MR IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Iomab-B
GTTS-WQ15047MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA SRF-231
GTTS-WQ6690MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ13236MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-05335810
GTTS-WQ9210MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA IMMU-106
GTTS-WQ13054MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PEG-IFN-SA
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW